Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? (Q42647694)

4 November 2017

Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? (English)

1 reference

4 November 2017

1 reference

M M Regan

1

1 reference

4 November 2017

O Pagani

2

1 reference

4 November 2017

B Walley

3

1 reference

4 November 2017

R Torrisi

4

1 reference

4 November 2017

E A Perez

5

1 reference

4 November 2017

P Francis

6

1 reference

4 November 2017

G F Fleming

7

1 reference

4 November 2017

K N Price

8

1 reference

4 November 2017

B Thürlimann

9

1 reference

4 November 2017

R Maibach

10

1 reference

4 November 2017

M Castiglione-Gertsch

11

1 reference

4 November 2017

A S Coates

12

1 reference

4 November 2017

A Goldhirsch

13

1 reference

4 November 2017

R D Gelber

14

1 reference

4 November 2017

SOFT/TEXT/PERCHE Steering Committee

15

1 reference

4 November 2017

International Breast Cancer Study Group

16

1 reference

4 November 2017

5 March 2008

1 reference

4 November 2017

1 reference

4 November 2017

19

1 reference

4 November 2017

1231-1241

1 reference

4 November 2017

7

1 reference

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

4 November 2017

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Clinical trial update: International Breast Cancer Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Adjuvant hormonal therapy for premenopausal women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Estrogen-receptor biology: continuing progress and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Gene expression profiling of breast cancer: a new tumor marker

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDN037

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDN037

1 reference

4 November 2017

1 reference